Elunetirom shows synaptogenic promise as Autobahn eyes pivotal trials in depression
Autobahn’s elunetirom may offer a novel neuroplasticity-driven treatment for depression. Find out what its latest data mean for the future of MDD therapy.
Pharma & Biotech
Pharma & Biotech
Can TN-001 avoid hallucinogenic pitfalls while delivering rapid antidepressant effects?
Transneural’s TN-001 shows rapid neuroplasticity without hallucinogenic effects. Find out what this could mean for MDD and PTSD treatment strategies.